Entero Regains Nasdaq Compliance With Grid AI Acquisition
Entero Therapeutics (NASDAQ:ENTO) announced on October 30, 2025 that it acquired 100% of Grid AI Corp., has made Grid AI a wholly owned subsidiary, and has regained compliance with Nasdaq Listing Rule 5550(b)(1). The company describes its platform as positioned at the intersection of AI, hyperscale data centers, power grids and global infrastructure to pursue grid-edge orchestration and AI-driven infrastructure optimization.
The release also notes forward-looking statements and specifically references the need to obtain shareholder approval for common stock underlying preferred stock issued in the acquisition and uncertainty about future results.
Entero Therapeutics (NASDAQ:ENTO) ha annunciato il 30 ottobre 2025 di aver acquisito il 100% di Grid AI Corp., trasformando Grid AI in una controllata interamente posseduta e aver ritrovato la conformità con la Nasdaq Listing Rule 5550(b)(1). L'azienda descrive la sua piattaforma come posizionata all'intersezione di AI, data center iperscalabili, reti elettriche e infrastrutture globali per perseguire l'orchestrazione al margine della rete e l'ottimizzazione dell'infrastruttura guidata dall'AI.
Il comunicato include anche dichiarazioni previsionali e, in particolare, fa riferimento alla necessità di ottenere l'approvazione degli azionisti per le azioni ordinarie sottostanti al capitale privilegiato emesso nell'acquisizione e all'incertezza sui risultati futuri.
Entero Therapeutics (NASDAQ:ENTO) anunció el 30 de octubre de 2025 que adquirió el 100% de Grid AI Corp., convirtió Grid AI en una filial de propiedad total y ha restablecido el cumplimiento con la Nasdaq Listing Rule 5550(b)(1). La compañía describe su plataforma como ubicada en la intersección de IA, centros de datos a gran escala, redes eléctricas y la infraestructura global para perseguir la orquestación en el borde de la red y la optimización de la infraestructura impulsada por IA.
El comunicado también señala declaraciones prospectivas y, específicamente, hace referencia a la necesidad de obtener aprobación de los accionistas para las acciones comunes subyacentes al stock preferente emitido en la adquisición y a la incertidumbre sobre los resultados futuros.
Entero Therapeutics (NASDAQ:ENTO)는 2025년 10월 30일에 Grid AI Corp.의 100%를 인수했고 Grid AI를 전액 소유 자회사로 만들었으며 나스닥 상장 규칙 5550(b)(1)에 대한 준수 회복를 달성했다고 발표했다. 회사는 플랫폼을 AI, 하이퍼스케일 데이터 센터, 전력망과 글로벌 인프라의 교차점에 위치해 네트워크 가장자리의 오케스트레이션과 AI 주도 인프라 최적화를 추진한다고 설명한다.
공고는 또한 미래 예측 진술을 언급하며 특히 인수에 의해 발행된 우선주를 기초로 하는 보통주에 대한 주주 승인의 필요성과 향후 결과에 대한 불확실성을 지적한다.
Entero Therapeutics (NASDAQ:ENTO) a annoncé le 30 octobre 2025 avoir acquis 100 % de Grid AI Corp., faisant de Grid AI une filiale entièrement détenue et avoir retrouvé la conformité avec la Nasdaq Listing Rule 5550(b)(1). La société décrit sa plateforme comme positionnée à l'intersection de l'IA, des data centers hyperscalables, des réseaux électriques et des infrastructures mondiales pour poursuivre l'orchestration en bord de réseau et l'optimisation des infrastructures pilotée par l'IA.
Le communiqué mentionne également des déclarations prospectives et fait spécifiquement référence à la nécessité d'obtenir l'approbation des actionnaires pour les actions ordinaires sous-jacentes aux actions privilégiées émises lors de l'acquisition et à l'incertitude concernant les résultats futurs.
Entero Therapeutics (NASDAQ:ENTO) gab am 30. Oktober 2025 bekannt, dass es 100 % von Grid AI Corp. erworben hat, Grid AI zu einer vollständig Tochtergesellschaft gemacht hat und die Einhaltung der Nasdaq Listing Rule 5550(b)(1) wiedererlangt hat. Das Unternehmen beschreibt seine Plattform als an der Schnittstelle von KI, hyperskalierbaren Rechenzentren, Stromnetzen und globaler Infrastruktur positioniert, um Netzrand-Orchestrierung und KI-gesteuerte Infrastrukturoptimierung zu verfolgen.
Die Mitteilung verweist auch auf Zukunftsprognosen und nennt insbesondere die Notwendigkeit einer Aktionärsfreigabe für Stammaktien, die den in der Übernahme ausgegebenen Vorzugsaktien zugrunde liegen, sowie Unsicherheit über zukünftige Ergebnisse.
Entero Therapeutics (ناسداك: ENTO) أعلنت في 30 أكتوبر 2025 أنها استحوذت على 100% من Grid AI Corp.، وجعلت Grid AI شركة تابعة مملوكة بالكامل، و استعادت الامتثال لقاعدة الإدراج 5550(b)(1) في ناسداك. تصف الشركة منصتها بأنها تقطع عند تقاطع الذكاء الاصطناعي، مراكز البيانات عالية السعة، شبكات الكهرباء والبنية التحتية العالمية من أجل تنظيم حافة الشبكة وتحسين البنية التحتية مدفوعة بالذكاء الاصطناعي.
تشير البيان أيضاً إلى التصريحات المستقبلية وتذكر بشكل خاص الحاجة إلى الحصول على موافقة المساهمين على الأسهم العادية التي تكون أساس الأسهم الممتازة المصدرة في عملية الاستحواذ وعدم اليقين بشأن النتائج المستقبلية.
- Acquired 100% of Grid AI Corp.
- Regained Nasdaq compliance under Rule 5550(b)(1)
- Grid AI added as wholly owned subsidiary
- Positioning in AI and hyperscale data center market
- Shareholder approval required for common stock underlying issued preferred stock
- Forward-looking outcomes may differ materially from expectations
BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics, Inc. ("Entero" or the "Company") (NASDAQ:ENTO) is pleased to announce that, as a result of the acquisition of
Entero's publicly‑listed platform now sits at the intersection of AI, data centers, power grids, and global infrastructure. The acquisition of Grid AI, now operating as a wholly‑owned subsidiary of Entero, enables the Company to participate in one of the most significant secular growth arenas of the coming decade: hyperscale data centers, grid‑edge orchestration, and AI‑driven infrastructure optimization.
Forward‑Looking Statements
This press release contains forward‑looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the strategic benefits of the acquisition, the integration of Grid AI, the ability to maintain compliance with Nasdaq's listing criteria in connection with the Grid AI acquisition and otherwise, the ability to obtain shareholder approval of the common stock underlying the preferred stock issued in the Grid AI acquisition, expected future operating results, market opportunities, and the Company's growth strategy. Actual results may differ materially due to risks and uncertainties. The Company undertakes no obligation to update forward‑looking statements except as required by law.
About Entero Therapeutics, Inc.
Entero Therapeutics (NASDAQ:ENTO) is a publicly listed company. The Company's programs address significant unmet needs in gastrointestinal (GI) health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Following the acquisition of Grid AI, the Company is continuing these prior operations and is also repositioning into the infrastructure, AI and data‑centre orchestration space. Entero operates Grid AI as a wholly‑owned subsidiary and intends to leverage its public‑market listing and corporate resources to scale the new venture.
About Grid AI
Grid AI is an AI‑driven, grid‑edge software and device orchestration platform enabling business, utility, and hyperscaler customers to forecast, optimize, and dispatch flexible demand, DERs and compute assets. The platform supports major ML frameworks, offers rapid scale across cloud GPU/CPU infrastructure, and is designed to deliver SaaS‑like recurring revenue.
Investor & Media Contacts:
Entero Investor Relations
investors@enterothera.com
SOURCE: Entero Therapeutics, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Entero (ENTO) announce on October 30, 2025 about Grid AI?
How did the Grid AI acquisition affect Entero's Nasdaq status (ENTO)?
What strategic markets does Entero (ENTO) say the Grid AI deal targets?
Does the Entero (ENTO) announcement mention shareholder approvals?
Are there risks noted in Entero's (ENTO) Grid AI acquisition announcement?
